Therefore, alternative strategies for HER2-overexpressing breast cancer, such as new potent HER2 target compounds, targeted pathways, or dual therapy, need to be developed to improve clinical outcomes and overcome resistance. This evidence concerns the gene ERBB2 and breast cancer.